Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera Therapeutics appoints Christopher Hite to Board of Directors
Filed March 9, 2026 · Period ending March 5, 2026 · ~1 min read
Key Changes
-
low
Christopher Hite appointed as Class III Director effective March 5, 2026, with term expiring at 2027 Annual Meeting. Appointment expands Board oversight.
Item 5.02 verify on EDGAR → -
low
Hite receives standard new director compensation: stock options for 24,937 shares at $38.85 exercise price, vesting monthly over three years, plus $45,000 annual cash retainer (pro-rated for 2026).
Item 5.02 verify on EDGAR →
Summary
Vera Therapeutics expanded its Board of Directors with the appointment of Christopher Hite as a Class III Director, effective March 5, 2026. His initial term will run through the company's 2027 Annual Meeting of Stockholders. The appointment follows standard governance practices for board expansion.
Hite's compensation package is consistent with the company's existing Non-Employee Director Compensation Policy, including an initial stock option grant for 24,937 shares at $38.85 per share (vesting monthly over three years) and a $45,000 annual cash retainer, pro-rated for 2026. This is a routine board appointment with no material impact on operations or strategy. Retail investors should watch for any committee assignments announced for Hite in future proxy filings, which would indicate his specific oversight role within the Board structure.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In addition, in accordance with the Policy, Mr. Hite will also receive an annual cash retainer of $45,000 for his service on the Board which will be pro-rated for 2026.
Mr. Hite will receive an annual cash retainer of $45,000 for his Board service, pro-rated for 2026. This is standard compensation for non-employee directors and follows the company's existing director compensation policy.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify